Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Ephedrine ban

This article was originally published in The Tan Sheet

Executive Summary

Ephedrine ban: Proposed by Nassua County Executive Thomas Gulotta for sales of herbal "stimulants" containing ephedrine. Announced on April 16, the proposed legislative action is being drafted and is expected to be forwarded to the legislature the week of April 22. Gulotta called for the sales ban in response to the March death of a 20-year-old county resident who allegedly consumed a large amount of an ephedrine-containing herbal product. On March 5, FDA's regional office in Orlando, Fla. sent a warning letter to Jacksonville Beach, Fla.-based Carribbean Connection regarding a false ad claim that the company's "Herbal Ecstasy" was "FDA-approved." Gulotta cited Herbal Ecstasy as one of the problematic herbal products currently available in "novelty stores, health stores, smoke shops and beauty salons"...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS085009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel